DOCSLIB.ORG

Proprotein Convertase Enzymes FURIN and PCSK7 in Immune Regulation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proprotein Convertase Enzymes FURIN and PCSK7 in Immune Regulation ANNA OKSANEN Proprotein Convertase Enzymes FURIN and PCSK7 in Immune Regulation ACADEMIC DISSERTATION To be presented, with the permission of the Board of the BioMediTech of the University of Tampere, for public discussion in the Small Auditorium of Building M, Pirkanmaa Hospital District, Teiskontie 35, Tampere, on May 29th, 2015, at 12 o’clock. UNIVERSITY OF TAMPERE ANNA OKSANEN Proprotein Convertase Enzymes FURIN and PCSK7 in Immune Regulation Acta Universitatis Tamperensis 2055 Tampere University Press Tampere 2015 ACADEMIC DISSERTATION University of Tampere, BioMediTech Finland Supervised by Reviewed by Docent Marko Pesu Docent Petteri Arstila University of Tampere University of Helsinki Finland Finland Docent Zhi Jane Chen University of Turku Finland The originality of this thesis has been checked using the Turnitin OriginalityCheck service in accordance with the quality management system of the University of Tampere. Copyright ©2015 Tampere University Press and the author Cover design by Mikko Reinikka Distributor: [email protected] https://verkkokauppa.juvenes.fi Acta Universitatis Tamperensis 2055 Acta Electronica Universitatis Tamperensis 1547 ISBN 978-951-44-9802-2 (print) ISBN 978-951-44-9803-9 (pdf) ISSN-L 1455-1616 ISSN 1456-954X ISSN 1455-1616 http://tampub.uta.fi Suomen Yliopistopaino Oy – Juvenes Print Tampere 2015 441 729 Painotuote “I need to write down my observations. Even the tiniest ones; they are the most important.” -Tove Jansson (1914-2001) CONTENTS LIST OF ORIGINAL COMMUNICATIONS ............................................................. 7 ABBREVIATIONS ............................................................................................................ 8 ABSTRACT........................................................................................................................ 11 TIIVISTELMÄ .................................................................................................................. 13 1 INTRODUCTION ....................................................................................................... 15 2 REVIEW OF THE LITERATURE........................................................................... 17 2.1 The immune system ............................................................................................... 17 2.2 CD4+ T helper cells ............................................................................................... 20 2.2.1 T helper cell differentiation ........................................................................... 20 2.2.2 T helper cell function ...................................................................................... 24 2.3 Biology of the proprotein convertase (PCSK) enzymes ................................... 26 2.3.1 The PCSK family ............................................................................................. 27 2.3.2 Tissue expression and subcellular localization of PCSKs ......................... 28 2.3.3 Substrates of PCSKs ....................................................................................... 30 2.3.4 Interaction studies on PCSKs ....................................................................... 32 2.4 PCSKs in health and disease ................................................................................. 33 2.4.1 Animal models and human patients ............................................................. 34 2.4.2 PCSKs in regulating the immune system ..................................................... 38 2.4.3 PCSKs in the pathogenesis of atherosclerosis ............................................ 42 2.4.4 Therapeutic potential of targeting PCSKs ................................................... 43 2.5 Studying the function of PCSKs in zebra fish ................................................... 44 3 AIMS OF THE STUDY .............................................................................................. 47 4 MATERIALS AND METHODS .............................................................................. 48 4.1 Experimental animals (I-II) .................................................................................. 48 4.2 Human subjects (III) ............................................................................................. 48 4.3 Antibodies (I-III).................................................................................................... 49 4.4 Plasmid constructs and cloning (I, II) ................................................................. 50 4.5 Cell culture, transfection, and generation of stable cell lines (I-II) ................ 50 4.6 Cell purification, activation, and flow cytometry (I, III) .................................. 51 4.7 Biochemical analysis of proteins (I-III) .............................................................. 52 4.7.1 Cell lysis and Western blotting (I-III) ........................................................... 52 4.7.2 Strep-tag affinity purification and mass spectrometry (I) .......................... 53 4.7.3 Co-immunoprecipitation and co-immunofluorescence (I) ....................... 54 4.8 F-actin polymerization assay (I) ........................................................................... 54 4.9 Cytokine measurements (I, III) ............................................................................ 55 4.10 Quantitative real-time PCR, Q-RT-PCR (I-III) .............................................. 55 4.11 Statistical analyses (I-III) ..................................................................................... 56 4.12 Ethical considerations (I-III) .............................................................................. 56 5 SUMMARY OF THE RESULTS .............................................................................. 58 5.1 FURIN is a central regulator of T cell-mediated immunity in mouse (I) ...... 58 5.1.1 FURIN is critical for host resistance against Toxoplasma gondii ............ 58 5.1.2 Th1/Th2 balance is affected by FURIN deficiency ................................... 59 5.1.3 FURIN inhibits IL-4Rα surface expression on naïve Th cells ................. 60 5.1.4 RAC/DOCK2 is a novel FURIN interacting complex in T cells ............ 61 5.2 PCSK7 is essential for zebra fish development and TGFβ1a regulation (II) 62 5.2.1 Embryogenesis and immune system gene expression are affected by PCSK7 silencing ........................................................................................................ 63 5.2.2 PCSK7 regulates the expression and proteolytic cleavage of TGFβ1a ... 64 5.3 FURIN is upregulated in human atherosclerotic plaques (III) ........................ 65 5.3.1 Expression of FURIN is induced upon immune cell activation .............. 66 5.3.2 BAFF and APRIL levels are not elevated in atherosclerotic patient serum .......................................................................................................................... 66 6 DISCUSSION ................................................................................................................ 68 6.1 PCSKs mediate both redundant and unique immunomodulatory functions ......................................................................................................................... 68 6.2 Expression of FURIN is critical for immune cell function .............................. 71 6.3 Interaction studies reveal new concepts of PCSK-mediated cellular regulation ........................................................................................................................ 72 7 CONCLUSIONS AND FUTURE PERSPECTIVES ............................................ 76 8 ACKNOWLEDGEMENTS ....................................................................................... 78 9 REFERENCES .............................................................................................................. 81 10 ORIGINAL COMMUNICATIONS ....................................................................... 99 LIST OF ORIGINAL COMMUNICATIONS This thesis is based on the following original publications, which are referenced in the text by their Roman numerals (I-III): I Oksanen A, Aittomäki S, Jankovic D, Ortutay Z, Pulkkinen K, Hämäläinen S, Rokka A, Corthals GL, Watford WT, Junttila I, O'Shea JJ, Pesu M. Proprotein Convertase FURIN Constrains Th2 Differentiation and Is Critical for Host Resistance against Toxoplasma gondii. J Immunol 2014;193(11)5470-9. II Turpeinen H*, Oksanen A*, Kivinen V, Kukkurainen S, Uusimäki A, Rämet M, Parikka M, Hytönen VP, Nykter M, Pesu M. Proprotein Convertase Subtilisin/Kexin Type 7 (PCSK7) Is Essential for the Zebrafish Development and Bioavailability of Transforming Growth Factor β1a (TGFβ1a). J Biol Chem 2013;288(51)36610-23. III Turpeinen H, Raitoharju E, Oksanen A, Oksala N, Levula M, Lyytikäinen LP, Järvinen O, Creemers JW, Kähönen M, Laaksonen R, Pelto-Huikko M, Lehtimäki T, Pesu M. Proprotein convertases in human atherosclerotic plaques: the overexpression of FURIN and its substrate cytokines BAFF and APRIL. Atherosclerosis 2011;219(2)799-806. *) Equal contribution The original publications have been reproduced with the permission of the copyright holders. 7 ABBREVIATIONS ADAM a disintegrin and metalloproteinase APC antigen presenting cell APRIL tumor necrosis factor ligand superfamily member 13 BACH2 BTB and CNC homology 2 BAFF tumor necrosis factor ligand superfamily member 13B BCR B cell receptor BMP bone morphogenetic protein CD cluster of differentiation CHD coronary heart disease CD4cre-furf/f
Load more

Recommended publications
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Intracellular Peptides: from Discovery to Function
    e u p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 143–151 Available online at www.sciencedirect.com ScienceDirect journal homepage: http://www.elsevier.com/locate/euprot Intracellular peptides: From discovery to function a,∗ b a,c d,∗∗ Emer S. Ferro , Vanessa Rioli , Leandro M. Castro , Lloyd D. Fricker a Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, SP, Brazil b Special Laboratory of Applied Toxicology-CeTICS, Butantan Institute, São Paulo, SP, Brazil c Department of Biophysics, Federal University of São Paulo, São Paulo, SP, Brazil d Department of Molecular Pharmacology and Neuroscience, Albert Einstein College of Medicine, Bronx, NY, USA a r t i c l e i n f o a b s t r a c t Article history: Peptidomics techniques have identified hundreds of peptides that are derived from proteins Received 8 October 2013 present mainly in the cytosol, mitochondria, and/or nucleus; these are termed intracellular Received in revised form peptides to distinguish them from secretory pathway peptides that function primarily out- 29 November 2013 side of the cell. The proteasome and thimet oligopeptidase participate in the production and Accepted 14 February 2014 metabolism of intracellular peptides. Many of the intracellular peptides are common among mouse tissues and human cell lines analyzed and likely to perform a variety of functions Keywords: within cells. Demonstrated functions include the modulation of signal transduction, mito- Peptides chondrial stress, and development; additional functions will likely be found for intracellular Cell signaling peptides.
    [Show full text]
  • A Case of Prohormone Convertase Deficiency Diagnosed with Type 2 Diabetes
    Turkish CASE REPORT Archives of DOI: 10.14744/TurkPediatriArs.2020.36459 Pediatrics A case of prohormone convertase deficiency diagnosed with type 2 diabetes Gülin Karacan Küçükali1 , Şenay Savaş Erdeve1 , Semra Çetinkaya1 , Melikşah Keskin1 , Ayşe Derya Buluş2 , Zehra Aycan1 1Department of Pediatric Endocrinology, University of Health Science, Dr. Sami Ulus Obstetrics and Gynecology, Children’s Health and Disease Training and Research Hospital, Ankara, Turkey 2Department of Pediatric Endocrinology, University of Health Science, Keçiören Training and Research Hospital, Ankara, Turkey What is already known ABSTRACT on this topic? Prohormone convertase 1/3, encoded by the proprotein convertase subtilisin/kexin type 1 gene, • Prohormone convertase defi- is essential for processing prohormones; therefore, its deficiency is characterized by a defi- ciency is characterized by a de- ciency of variable levels in all hormone systems. Although a case of postprandial hypoglycemia ficiency of variable levels in all has been previously reported in the literature, prohormone convertase insufficiency with type hormone systems. 2 diabetes mellitus has not yet been reported. Our case, a 14-year-old girl, was referred due to • Postprandial hypoglycemia is a excess weight gain. She was diagnosed as having type 2 diabetes mellitus based on laboratory disorder of glucose metabolism test results. Prohormone convertase deficiency was considered due to the history of resistant reported in this disease. diarrhea during the infancy period and her rapid weight gain. Proinsulin level was measured as >700 pmol/L(3.60-22) during diagnosis. In genetic analysis, a c.685G> T(p.V229F) homozygous mutation in the PCSK1 gene was detected and this has not been reported in relation to this dis- order.
    [Show full text]
  • Electronic Supplementary Material (ESI) for Analyst. This Journal Is © the Royal Society of Chemistry 2020
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 Table S1.
    [Show full text]
  • 2014-Platform-Abstracts.Pdf
    American Society of Human Genetics 64th Annual Meeting October 18–22, 2014 San Diego, CA PLATFORM ABSTRACTS Abstract Abstract Numbers Numbers Saturday 41 Statistical Methods for Population 5:30pm–6:50pm: Session 2: Plenary Abstracts Based Studies Room 20A #198–#205 Featured Presentation I (4 abstracts) Hall B1 #1–#4 42 Genome Variation and its Impact on Autism and Brain Development Room 20BC #206–#213 Sunday 43 ELSI Issues in Genetics Room 20D #214–#221 1:30pm–3:30pm: Concurrent Platform Session A (12–21): 44 Prenatal, Perinatal, and Reproductive 12 Patterns and Determinants of Genetic Genetics Room 28 #222–#229 Variation: Recombination, Mutation, 45 Advances in Defining the Molecular and Selection Hall B1 Mechanisms of Mendelian Disorders Room 29 #230–#237 #5-#12 13 Genomic Studies of Autism Room 6AB #13–#20 46 Epigenomics of Normal Populations 14 Statistical Methods for Pedigree- and Disease States Room 30 #238–#245 Based Studies Room 6CF #21–#28 15 Prostate Cancer: Expression Tuesday Informing Risk Room 6DE #29–#36 8:00pm–8:25am: 16 Variant Calling: What Makes the 47 Plenary Abstracts Featured Difference? Room 20A #37–#44 Presentation III Hall BI #246 17 New Genes, Incidental Findings and 10:30am–12:30pm:Concurrent Platform Session D (49 – 58): Unexpected Observations Revealed 49 Detailing the Parts List Using by Exome Sequencing Room 20BC #45–#52 Genomic Studies Hall B1 #247–#254 18 Type 2 Diabetes Genetics Room 20D #53–#60 50 Statistical Methods for Multigene, 19 Genomic Methods in Clinical Practice Room 28 #61–#68 Gene Interaction
    [Show full text]
  • 1.2.Obesity-Pathophysiology.Pdf
    What Is the Disease of Obesity? Obesity Pathophysiology Obesity Has Multiple Pathophysiologic Origins Epigenetic Environmental Genetic Obesity Sociocultural Physiologic Behavioral Bray GA, et al. Lancet. 2016;387:1947-1956. 2 Obesity Pathophysiology Genetic and Epigenetic Origins 3 Genetic Determinants of Obesity Supported by Genome-Wide Association Studies Gene Tissue expressed Gene product / role in energy balance MC4R Adipocyte, hypothalamus, liver Melanocortin 4 receptor / Appetite stimulation; monogenic cause of obesity ADRB3 Visceral adipose tissue β3-Adrenergic receptor / Regulates lipolysis PCSK1 Neuroendocrine cells (brain, Proprotein convertase 1 / Conversion of hormones (including insulin) pituitary and adrenal glands) into metabolically active forms BDNF Hypothalamus Brain-derived neurotrophic factor / Appetite stimulation; regulated by MC4R signaling and nutritional state LCT Intestinal epithelial cells Lactase / Digestion of lactose MTNR1B Nearly ubiquitous Melantonin receptor 1 B / Regulation of circadian rhythms TLR4 Adipocyte, macrophage Toll-like receptor 4 / Lipolysis, inflammatory reactions ENPP1 Nearly ubiquitous Ecotnucleotide pyrophosphatase/phosphodiesterase 1 / Inhibits tyrosine kinase activity of the insulin receptor, downregulating insulin signaling and decreasing insulin sensitivity FGFR1 Adipose, hypothalamus Fibroblast growth factor receptor 1 / Hypothalamic regulation of food intake and physical activity LEP, LEPR Adipocyte Leptin, leptin receptor / Appetite inhibition den Hoed M, Loos RJF. In: Bray GA, Bouchard
    [Show full text]
  • Discovery of an Allosteric Site on Furin, Contributing to Potent Inhibition: a Promising Therapeutic for the Anemia of Chronic Inflammation
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 2014-07-01 Discovery of an Allosteric Site on Furin, contributing to Potent Inhibition: A Promising Therapeutic for the Anemia of Chronic Inflammation Andrew Jacob Gross Brigham Young University Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Chemistry Commons BYU ScholarsArchive Citation Gross, Andrew Jacob, "Discovery of an Allosteric Site on Furin, contributing to Potent Inhibition: A Promising Therapeutic for the Anemia of Chronic Inflammation" (2014). Theses and Dissertations. 6537. https://scholarsarchive.byu.edu/etd/6537 This Dissertation is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected]. Discovery of an Allosteric Site on Furin, Contributing to Potent Inhibition: A Promising Therapeutic for the Anemia of Chronic Inflammation Andrew J. Gross A dissertation submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Doctor of Philosophy Richard K. Watt, Chair Dixon J. Woodbury Roger G. Harrison Chad R. Hancock John T. Prince Department of Chemistry and Biochemistry Brigham Young University July 2014 Copyright © 2014 Andrew J. Gross All Rights Reserved ABSTRACT Discovery of an Allosteric site on Furin, Contributing to potent Inhibition: A promising Therapeutic for the Anemia of Chronic Inflammation Andrew J. Gross Department of Chemistry and Biochemistry, BYU Doctor of Philosophy Anemia of chronic inflammation (ACI) is a condition that develops in a setting of chronic immune activation. ACI is characterized and triggered by inflammatory cytokines and the disruption of iron homeostasis.
    [Show full text]
  • PCSK9 Biology and Its Role in Atherothrombosis
    International Journal of Molecular Sciences Review PCSK9 Biology and Its Role in Atherothrombosis Cristina Barale, Elena Melchionda, Alessandro Morotti and Isabella Russo * Department of Clinical and Biological Sciences, Turin University, I-10043 Orbassano, TO, Italy; [email protected] (C.B.); [email protected] (E.M.); [email protected] (A.M.) * Correspondence: [email protected]; Tel./Fax: +39-011-9026622 Abstract: It is now about 20 years since the first case of a gain-of-function mutation involving the as- yet-unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 (PCSK9), was described. It was soon clear that this protein would have been of huge scientific and clinical value as a therapeutic strategy for dyslipidemia and atherosclerosis-associated cardiovascular disease (CVD) management. Indeed, PCSK9 is a serine protease belonging to the proprotein convertase family, mainly produced by the liver, and essential for metabolism of LDL particles by inhibiting LDL receptor (LDLR) recirculation to the cell surface with the consequent upregulation of LDLR- dependent LDL-C levels. Beyond its effects on LDL metabolism, several studies revealed the existence of additional roles of PCSK9 in different stages of atherosclerosis, also for its ability to target other members of the LDLR family. PCSK9 from plasma and vascular cells can contribute to the development of atherosclerotic plaque and thrombosis by promoting platelet activation, leukocyte recruitment and clot formation, also through mechanisms not related to systemic lipid changes. These results further supported the value for the potential cardiovascular benefits of therapies based on PCSK9 inhibition. Actually, the passive immunization with anti-PCSK9 antibodies, evolocumab and alirocumab, is shown to be effective in dramatically reducing the LDL-C levels and attenuating CVD.
    [Show full text]
  • PACE4 Expression in Mouse Basal Keratinocytes Results in Basement Membrane Disruption and Acceleration of Tumor Progression
    Research Article PACE4 Expression in Mouse Basal Keratinocytes Results in Basement Membrane Disruption and Acceleration of Tumor Progression Daniel E. Bassi,1,3 Ricardo Lopez De Cicco,1 Jonathan Cenna,1 Samuel Litwin,2 Edna Cukierman,2 and Andres J.P. Klein-Szanto1,3 Departments of 1Pathology and 2Biomathematics and Biostatistics, and 3Tumor Cell Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania Abstract and studying the in vivo effects after overexpressing genes, such as h Collagen type IV degradation results in disruption and transforming growth factor- (3), epidermal growth factor receptor breakdown of the normal basement membrane architecture, (4), and insulin-like growth factor (5). a key process in the initiation of tumor microinvasion into the Proprotein convertases constitute a family of serine proteases that activate their cognate substrates by limited proteolysis at consensus connective tissue. PACE4, a proprotein convertase, activates # membrane type matrix metalloproteinases (MT-MMPs) that in sequence RXR/KR (6). Many of these, such as insulin-like growth turn process collagenase type IV. Because PACE4 is overex- factor-I (7) and its receptor (8), membrane-type matrix metal- pressed in skin carcinomas and in vitro overexpression of loproteinase (MT-MMP; refs. 9, 10), and integrins (11–14) have direct PACE4 resulted in enhanced invasiveness, we investigated roles in tumor progression and metastasis. Although proprotein whetherornotin vivo PACE4 expression leads to the convertases recognize and cleave a specific sequence, variations in the amino acid sequences that surround this motif, as well as acquisition of invasiveness and increased tumorigenesis. Two transgenic mouse lines were designed by targeting PACE4 to preferences in K or R preceding the COOH-terminal R, account for the epidermal basal keratinocytes.
    [Show full text]
  • Functional Annotation of the Human Retinal Pigment Epithelium
    BMC Genomics BioMed Central Research article Open Access Functional annotation of the human retinal pigment epithelium transcriptome Judith C Booij1, Simone van Soest1, Sigrid MA Swagemakers2,3, Anke HW Essing1, Annemieke JMH Verkerk2, Peter J van der Spek2, Theo GMF Gorgels1 and Arthur AB Bergen*1,4 Address: 1Department of Molecular Ophthalmogenetics, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences (KNAW), Meibergdreef 47, 1105 BA Amsterdam, the Netherlands (NL), 2Department of Bioinformatics, Erasmus Medical Center, 3015 GE Rotterdam, the Netherlands, 3Department of Genetics, Erasmus Medical Center, 3015 GE Rotterdam, the Netherlands and 4Department of Clinical Genetics, Academic Medical Centre Amsterdam, the Netherlands Email: Judith C Booij - [email protected]; Simone van Soest - [email protected]; Sigrid MA Swagemakers - [email protected]; Anke HW Essing - [email protected]; Annemieke JMH Verkerk - [email protected]; Peter J van der Spek - [email protected]; Theo GMF Gorgels - [email protected]; Arthur AB Bergen* - [email protected] * Corresponding author Published: 20 April 2009 Received: 10 July 2008 Accepted: 20 April 2009 BMC Genomics 2009, 10:164 doi:10.1186/1471-2164-10-164 This article is available from: http://www.biomedcentral.com/1471-2164/10/164 © 2009 Booij et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • The Rs508487, Rs236911, and Rs236918 Genetic Variants
    cells Article The rs508487, rs236911, and rs236918 Genetic Variants of the Proprotein Convertase Subtilisin–Kexin Type 7 (PCSK7) Gene Are Associated with Acute Coronary Syndrome and with Plasma Concentrations of HDL-Cholesterol and Triglycerides Gilberto Vargas-Alarcón 1,† , Oscar Pérez-Méndez 1,2,† ,Héctor González-Pacheco 3 , Julián Ramírez-Bello 4 , Rosalinda Posadas-Sánchez 5 , Galileo Escobedo 6 and José Manuel Fragoso 1,* 1 Department of Molecular Biology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico; [email protected] (G.V.-A.); [email protected] (O.P.-M.) 2 School of Engineering and Sciences Campus CDMX, Tecnológico de Monterrey, Mexico City 14380, Mexico 3 Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico; [email protected] 4 Research Unit, Hospital Juárez de México, Mexico City 01460, Mexico; [email protected] 5 Department of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico; [email protected] 6 Unit of the Experimental Medicine, Hospital General de México, Dr. Eduardo Liceaga, Citation: Vargas-Alarcón, G.; Mexico City 06726, Mexico; [email protected] Pérez-Méndez, O.; González-Pacheco, * Correspondence: [email protected]; Tel.: +52-55-5573-2911 (ext. 26302); Fax: +52-55-5573-0926 H.; Ramírez-Bello, J.; Posadas- † The contributions by G. Vargas-Alarcón and O. Pérez-Méndez are equal and the order of authorship Sánchez, R.; Escobedo, G.; Fragoso, is arbitrary. J.M. The rs508487, rs236911, and rs236918 Genetic Variants of the Abstract: Dyslipidemia has a substantial role in the development of acute coronary syndrome (ACS). Proprotein Convertase Subtilisin– Previous reports, including genome-wide associations studies (GWAS), have shown that some genetic Kexin Type 7 (PCSK7) Gene Are variants of the proprotein convertase subtilisin–kexin type 7 (PCSK7) gene are associated with plasma Associated with Acute Coronary lipid levels.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan Et Al
    US 2004.008 1648A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan et al. (43) Pub. Date: Apr. 29, 2004 (54) ADZYMES AND USES THEREOF Publication Classification (76) Inventors: Noubar B. Afeyan, Lexington, MA (51) Int. Cl." ............................. A61K 38/48; C12N 9/64 (US); Frank D. Lee, Chestnut Hill, MA (52) U.S. Cl. ......................................... 424/94.63; 435/226 (US); Gordon G. Wong, Brookline, MA (US); Ruchira Das Gupta, Auburndale, MA (US); Brian Baynes, (57) ABSTRACT Somerville, MA (US) Disclosed is a family of novel protein constructs, useful as Correspondence Address: drugs and for other purposes, termed “adzymes, comprising ROPES & GRAY LLP an address moiety and a catalytic domain. In Some types of disclosed adzymes, the address binds with a binding site on ONE INTERNATIONAL PLACE or in functional proximity to a targeted biomolecule, e.g., an BOSTON, MA 02110-2624 (US) extracellular targeted biomolecule, and is disposed adjacent (21) Appl. No.: 10/650,592 the catalytic domain So that its affinity Serves to confer a new Specificity to the catalytic domain by increasing the effective (22) Filed: Aug. 27, 2003 local concentration of the target in the vicinity of the catalytic domain. The present invention also provides phar Related U.S. Application Data maceutical compositions comprising these adzymes, meth ods of making adzymes, DNA's encoding adzymes or parts (60) Provisional application No. 60/406,517, filed on Aug. thereof, and methods of using adzymes, Such as for treating 27, 2002. Provisional application No. 60/423,754, human Subjects Suffering from a disease, Such as a disease filed on Nov.
    [Show full text]